Record · corpus.blog/posts/01a0f576-b8a5-7351-b555-3062882fa016
A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · 30 September 2026 · 2 min read
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 9 October 2026).
A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Anchor phrases | 0 |
|---|---|
| External links | 0 |
| Words captured | 391 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post doesn't link to any pages we've captured.
Similar posts
HER2-Low Breast Cancer Treatment
verywellhealth.com
12 Sept 2026
The Most Effective HER2-Positive Breast Cancer Treatments
verywellhealth.com
20 Sept 2026
How HER2-Negative Breast Cancer Is Treated
verywellhealth.com
18 Sept 2026
Something wrong here? Report a problem